Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor
Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option
Melanoma – Combining Remicade or Cimzia might be better
Background Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is dangerous because it can rapidly spread to
Metastatic Breast Cancer – Utidelone plus Xeloda prolong life
Background Patients with advanced or metastatic breast cancer have very few effective treatment options. The lack of successful therapeutic strategies is reflected by a low
Glioblastoma – A new kid on the block, MDNA55
Background – Glioblastoma and MDNA55 The interleukin-4 receptor–targeted immunotherapeutic MDNA55 has demonstrated improved survival and disease control in patients with recurrent Glioblastoma who are treated
Glioblastoma – Is Keytruda combined with Virus the future?
Background A Phase 2 multi-center study was conducted to evaluate the virus, DNX-240, also called Tasadenoturev, in combination with the immunotherapy, Keytruda, in pateints with
Advanced Sarcoma – Keytruda plus Adriamycin
Background Anthracyclines is a class of drugs used in cancer chemotherapy. A wildly used Anthracycline drug is Doxorubicin also known as Adriamycin. These drugs are
Liver Cancer – Camrelizumab plus Rivoceranib show promise
Background This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer. Camrelizumab is anti-PD-1 immunotherapy drug given
Colorectal Cancer Patients May Live Longer With Coffee
Background – Colorectal cancer and coffee Several compounds found in coffee possess antioxidant, anti-inflammatory and insulin-sensitizing effects, which may contribute to anticancer activity, including colorectal
Esophageal cancer at 70 plus? Icotinib plus radiation
Background Concurrent chemoradiation therapy remains the standard therapy for unresectable Esophageal Squamous Cell Carcinoma patients. However, its feasibility and efficiency for older patients are being
Mesothelioma – New Approval of Drug Combination Treatment
Introduction On October 2nd 2020, the FDA approved Opdivo (Nivolumab) in combination with Yervoy (Ipilimumab) for the first-line treatment of patients with Malignant Pleural Mesothelioma
Breast, bowel and prostate cancers – A promising drug targeting DNA repair
Background DNA damage is the fundamental cause of cancer – leading to mutations in key genes that allow cancer cells to divide uncontrollably. But it
